Irbesartan Terapia

Irbesartan, the active ingredient in Irbesartan Terapia, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Terapia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent batch release, comprehensive documentation, and responsive technical support.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to lower blood pressure and protect renal function.

Hypertension: reduces systemic vascular resistance and lowers arterial pressure. Diabetic nephropathy: slows progression of kidney damage and reduces proteinuria. Heart failure: improves cardiac output and reduces hospitalization risk when used as adjunct therapy.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Fatigue - Hyperkalemia - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Acute renal failure - Hepatic injury - Myocardial infarction

When prescribing Irbesartan, clinicians should observe several safety considerations.

- Blood pressure monitoring: check regularly to avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium measurement: monitor for hyperkalemia, especially with concomitant potassium‑sparing agents. - Hepatic impairment caution: adjust use in patients with significant liver disease. - Pregnancy avoidance: discontinue in women who are pregnant or planning pregnancy due to fetal risk. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors: additive effect on potassium and renal function. - NSAIDs: can reduce antihypertensive effect and impair renal function. - Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - Loop or thiazide diuretics: may require dose adjustment of Irbesartan. - Cyclosporine or tacrolimus: heightened risk of nephrotoxicity.